{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:51Z","timestamp":1790996571923,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jfma.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T07:40:50Z","timestamp":1650267650000},"page":"2101-2108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders\u2014A cohort study"],"prefix":"10.1016","volume":"121","author":[{"given":"Sheng-Fu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-3792","authenticated-orcid":false,"given":"Yao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-9564","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2022.04.004_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/iju.12288","article-title":"Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly","volume":"21","author":"Sakakibara","year":"2014","journal-title":"Int J Urol : Off J Jpn Urol Assoc"},{"issue":"5","key":"10.1016\/j.jfma.2022.04.004_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11934-012-0269-6","article-title":"The incidence and etiology of overactive bladder in patients after cerebrovascular accident","volume":"13","author":"McKenzie","year":"2012","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.jfma.2022.04.004_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mds.20867","article-title":"Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management","volume":"21","author":"Winge","year":"2006","journal-title":"Mov Disord : Off J Mov Disord Soc"},{"key":"10.1016\/j.jfma.2022.04.004_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-11-13","article-title":"Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review","volume":"11","author":"Tapia","year":"2013","journal-title":"Health Qual Life Outcome"},{"issue":"3","key":"10.1016\/j.jfma.2022.04.004_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.jfma.2022.04.004_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib7","article-title":"Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases","volume":"11","author":"Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"issue":"3","key":"10.1016\/j.jfma.2022.04.004_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.jfma.2022.04.004_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jfma.2012.07.044","article-title":"The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment","volume":"113","author":"Chou","year":"2014","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.jfma.2022.04.004_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1464-410X.2004.05043.x","article-title":"Development and validation of a quality-of-life scale for Chinese patients with benign prostatic hyperplasia","volume":"94","author":"Shi","year":"2004","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.jfma.2022.04.004_bib11","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/j.1464-410X.2010.09684.x","article-title":"Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder","volume":"107","author":"Cartwright","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.jfma.2022.04.004_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000079697","article-title":"Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions","volume":"73","author":"Chen","year":"2004","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib14","first-page":"78","article-title":"Urinary dysfunction in Parkinson's disease","volume":"5","author":"Singer","year":"1998","journal-title":"Clin Neurosci"},{"issue":"5","key":"10.1016\/j.jfma.2022.04.004_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.71.5.600","article-title":"Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy","volume":"71","author":"Sakakibara","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/nau.22928","article-title":"Management of LUTS in patients with dementia and associated disorders","volume":"36","author":"Averbeck","year":"2017","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.jfma.2022.04.004_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp.2004.046243","article-title":"Lower urinary tract function in dementia of Lewy body type","volume":"76","author":"Sakakibara","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.jfma.2022.04.004_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2022.04.004_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1442-2042.2008.02045.x","article-title":"Detrusor contractility and overactive bladder in patients with cerebrovascular accident","volume":"15","author":"Natsume","year":"2008","journal-title":"Int J Urol : Off J Jpn Urol Assoc"},{"issue":"14","key":"10.1016\/j.jfma.2022.04.004_bib20","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25225","article-title":"Weak detrusor contractility correlates with motor disorders in Parkinson's disease","volume":"27","author":"Terayama","year":"2012","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jfma.2022.04.004_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/nau.23413","article-title":"Comparative efficacy and tolerability of solifenacin 5 mg\/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis","volume":"37","author":"Nazir","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869808997889","article-title":"Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors","volume":"6","author":"van de Waterbeemd","year":"1998","journal-title":"J Drug Target"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1124\/jpet.107.130294","article-title":"Progress in brain penetration evaluation in drug discovery and development","volume":"325","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"8","key":"10.1016\/j.jfma.2022.04.004_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"14","key":"10.1016\/j.jfma.2022.04.004_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carri\u00e8re","year":"2009","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jfma.2022.04.004_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.jfma.2022.04.004_bib27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.jfma.2022.04.004_bib28","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.jfma.2022.04.004_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/nau.23919","article-title":"Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study","volume":"38","author":"Mueller","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.jfma.2022.04.004_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.jfma.2022.04.004_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.03.009","article-title":"Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPi)","volume":"27","author":"Murchison","year":"2016","journal-title":"Park Relat Disord"},{"issue":"1","key":"10.1016\/j.jfma.2022.04.004_bib32","first-page":"117","article-title":"A review of solifenacin in the treatment of urinary incontinence","volume":"4","author":"Basra","year":"2008","journal-title":"Therapeut Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.jfma.2022.04.004_bib33","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-5347(05)64634-4","article-title":"Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats","volume":"168","author":"Kaidoh","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.jfma.2022.04.004_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (Synergy II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:48:21Z","timestamp":1760539701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622001474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0929664622001474"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.04.004","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders\u2014A cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}